Repatha (evolocumab) is a prescription drug used in certain situations to lower cholesterol and reduce serious heart-related risks. Repatha does this by attaching itself to a protein in your body ...

The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

Dosage for Repatha (evolocumab) may vary based on the condition it’s being used to treat. You might take 140 milligrams (mg) or 420 mg every 2 weeks, or you might take 420 mg monthly.

The results are a first shot across the bows of the rival PCSK9 ... LDL cholesterol-lowering effect of Merck's candidate. Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab ...

The stock shot up 12.5% ahead of the open ... Product sales were also up 22%. Sales of Repatha, Amgen’s cholesterol drug, increased 33% year over year to $517 million, the company said.